Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
25
IOBT Quote, Financials, Valuation and Earnings
Last price:
$0.68
Seasonality move
:
-37.46%
Day range:
$0.66 - $0.72
52-week range:
$0.32 - $2.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
53.56x
Volume:
1M
Avg. volume:
1.1M
1-year change:
-18.3%
Market cap:
$48.8M
Revenue:
--
EPS (TTM):
-$1.34
Analysts' Opinion
-
Consensus RatingIO Biotech, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.46, IO Biotech, Inc. has an estimated upside of 263.27% from its current price of $0.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.39 representing 100% downside risk from its current price of $0.68.
Fair Value
-
According to the consensus of 4 analysts, IO Biotech, Inc. has 263.27% upside to fair value with a price target of $2.46 per share.
IOBT vs. S&P 500
-
Over the past 5 trading days, IO Biotech, Inc. has underperformed the S&P 500 by -7.72% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IO Biotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IO Biotech, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter IO Biotech, Inc. reported revenues of --.
Earnings Growth
-
IO Biotech, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter IO Biotech, Inc. reported earnings per share of -$0.13.
Enterprise value:
36.2M
EV / Invested capital:
1.90x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-0.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$910K
Return On Assets:
-154.64%
Net Income Margin (TTM):
--
Return On Equity:
-297.46%
Return On Invested Capital:
-244.49%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$745K | -$831K | -$910K | -$205K | -$230K | |
| Operating Income | -$83.6M | -$96.4M | -$92.1M | -$26.5M | -$19.4M | |
| EBITDA | -$82.9M | -$95.6M | -$91.1M | -$26.3M | -$19.1M | |
| Diluted EPS | -$2.46 | -$1.37 | -$1.34 | -$0.36 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49.6M | $157.8M | $168.3M | $86.2M | $36.8M | |
| Total Assets | $52M | $162.2M | $172.6M | $89.9M | $40M | |
| Current Liabilities | $33.8M | $6.3M | $13M | $16.1M | $18.3M | |
| Total Liabilities | $33.8M | $8.7M | $15M | $17.4M | $39M | |
| Total Equity | $18.3M | $153.5M | $157.6M | $72.6M | $911K | |
| Total Debt | $28.3M | $2.3M | $2M | $1.3M | $17.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$61.5M | -$85.5M | -$81M | -$20.8M | -$18.5M | |
| Cash From Investing | -$560K | -$145K | -$69K | -$10K | -$4K | |
| Cash From Financing | $71.9M | -$10K | $32.8M | -- | $21.3M | |
| Free Cash Flow | -$62M | -$85.7M | -$81.1M | -$20.8M | -$18.5M | |
IOBT
Sector
Market Cap
$48.8M
$28.4M
Price % of 52-Week High
24.31%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-38.6%
-1.32%
1-Year Price Total Return
-18.3%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.70
200-day SMA
Sell
Level
$1.22
Bollinger Bands (100)
Sell
Level
0.71 - 1.89
Chaikin Money Flow
Buy
Level
25.8M
20-day SMA
Sell
Level
$0.77
Relative Strength Index (RSI14)
Sell
Level
42.32
ADX Line
Sell
Level
27.57
Williams %R
Neutral
Level
-64.246
50-day SMA
Sell
Level
$0.77
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
105.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.5059)
Sell
CA Score
(Annual)
Level (-2.9029)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.9149)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
Stock Forecast FAQ
In the current month, IOBT has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The IOBT average analyst price target in the past 3 months is $2.46.
-
Where Will IO Biotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that IO Biotech, Inc. share price will rise to $2.46 per share over the next 12 months.
-
What Do Analysts Say About IO Biotech, Inc.?
Analysts are divided on their view about IO Biotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IO Biotech, Inc. is a Sell and believe this share price will drop from its current level to $0.39.
-
What Is IO Biotech, Inc.'s Price Target?
The price target for IO Biotech, Inc. over the next 1-year time period is forecast to be $2.46 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is IOBT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IO Biotech, Inc. is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IOBT?
You can purchase shares of IO Biotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IO Biotech, Inc. shares.
-
What Is The IO Biotech, Inc. Share Price Today?
IO Biotech, Inc. was last trading at $0.68 per share. This represents the most recent stock quote for IO Biotech, Inc.. Yesterday, IO Biotech, Inc. closed at $0.68 per share.
-
How To Buy IO Biotech, Inc. Stock Online?
In order to purchase IO Biotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IOBT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IOBT
Sector
P/E ratio
--
23.66x
PEG ratio
-0.05x
-0.01x
P/B ratio
53.56x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
IOBT
Sector
Revenue growth
--
4.85%
Earnings growth
65.65%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.12
-$0.20
Profitability
IOBT
Sector
Profitability FY 2024
-$849K
$3.6M
Return on invested capital
-244.49%
-30.98%
Return on assets
-154.64%
-27.62%
Return on equity
-297.46%
-36.69%
Earnings Date
Last Earnings Date
May
15
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
IOBT
Sector
Total cash
$30.7M
$27.2M
Short term investments
--
$25.7M
Total assets
$67.7M
$79.9M
Long term debt
$17.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
